Thelansis

Relapsed or Refractory Classical Hodgkin’s Lymphoma Market Outlook Thelansis’s “Relapsed or Refractory Classical Hodgkin’s Lymphoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Relapsed or Refractory Classical Hodgkin’s Lymphoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and pat...

 Hodgkin lymphoma (HL) is a B-cell malignancy representing approximately 1 in 10 lymphomas diagnosed in the United States annually. Most patients with HL can be cured with chemotherapy; however, 5-10% will have the refractory disease to frontline therapy, and 10-30% will relapse. For those with relapsed or refractory (r/r) HL, salvage chemotherapy followed by autologous stem cell transplant (ASCT) is standard of care, but half of the patients will subsequently have disease progression. Relapse following ASCT has been associated with exceedingly poor prognosis with a median survival of only 26 months. ·        Hodgkin lymphoma (HL) is a B-cell malignancy, representing approximately 10% of all lymphomas seen in the United States, with an incidence of over 8500 cases per year. ·        Most patients with either limited or advanced stage cHL can be cured with chemotherapy; however, 5–10% will have the refractory disease to...